The Motley Fool

The SAR share price has jumped 1,000%. Should I buy now?

Image: GlaxoSmithKline

The SAR share price has seen blistering growth in 2021. Anyone buying just a few months ago will have more than doubled their money. So what’s behind the spike, and is it too late to buy now?

Sareum Holdings (LSE:SAR) is a mid-sized UK pharma founded in 2004. It’s a small molecule drug developer focused on cancer and autoimmune diseases. 

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Over the last 10 years the Sareum share price has been bumbling along not doing very much. But in the last 12 months it has leapt astonishingly quickly. That’s driven this unprofitable company to a £200m+ market cap. 

Why the SAR share price rocketed

On 7 January 2021, Sareum heard it had won patent approval in the US for an invention associated with its proprietary SCD-1802 kinase inhibitor programme. 

The granting of this patent in the US completes the protection of the intellectual property for our proprietary SDC-1802 programme across all major markets,” said chief scientific officer Dr John Reader.

Small molecule drugs have been the cornerstone of modern pharmaceuticals for over a century. Aspirin, for example, is a small molecule drug. They can enter cells easily because of their size and using science whizzbottery can even be ‘programmed’ to perform specific functions. 

On 15 June 2021 SAR issued a release saying it had received nearly £1.5m for 30m shares at 4.9p per share “by the same high net worth individual who subscribed to shares to the value of £900,000 as announced by the Company on 1 June 2021”. 

The cash will be used to progress its SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes, the company said. 

This white knight, whoever they are, clearly believes in the potential here. That’s left a lot of smaller investors with a Fear of Missing Out jumping aboard. Since this time last year the SAR share price has more than 10 bagged. So £5,000 invested in June 2020 would be worth approximately £55,250 today.

What the future holds

In December 2020, the UK’s Research and Innovation arm gave Sareum £174,000 to investigate the therapeutic potential of SDC-1801 for Covid-19. 

Sareum is aiming to complete preclinical studies of SDC-1801 by the end of Q3 this year. 

It says clinical trials as well as a potential Covid-19 application from the programme will also be developed. That will require more funding though, so shareholders should expect to be diluted further. 

The company has only reported one year of profit out of the last six. That’s not unusual for a growth company and especially not one dealing with experimental drugs. R&D costs are very high, which makes risk very high too. The associated rewards can be stonkingly good if the company hits on a winning product, though. 

Like all early-stage drug developers it takes vast sums of money to get these products out of the lab and into production. There is never 100% certainty that any product will work. And there are multiple points of potential failure along the road to market. Drugs could prove ineffective at clinical trials. The failure of its most important potential money-spinners could crash the Sareum share price. 

There’s clearly more to come from Sareum. Buying now offers potentially very high rewards, although at high risk. I would wait to hear more developments on the key results from SDC-1801 studies before buying more, to be honest. 

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Tom Rodgers owns shares in Sareum Holdings. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.